Ligand Pharmaceuticals Files 8-K on Shareholder Vote
Ticker: LGNZZ · Form: 8-K · Filed: Jun 9, 2025 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 8-K |
| Filed Date | Jun 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: LGND
TL;DR
LGND filed an 8-K for a shareholder vote - details TBD.
AI Summary
Ligand Pharmaceuticals Inc. filed an 8-K on June 9, 2025, to report on a submission of matters to a vote of security holders. The filing does not contain specific details about the vote itself, the proposals, or the outcome, but indicates that a vote was held or is being reported on.
Why It Matters
This filing signals that Ligand Pharmaceuticals Inc. has engaged its shareholders on a specific matter requiring a vote, which could impact corporate governance or strategic decisions.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.
Key Players & Entities
- LIGAND PHARMACEUTICALS INC (company) — Registrant
- June 9, 2025 (date) — Date of Report
FAQ
What specific matter was submitted for a vote of security holders?
The filing does not specify the exact matter submitted for a vote, only that it was a 'Submission of Matters to a Vote of Security Holders'.
When was the vote held or when is it being reported on?
The report is dated June 9, 2025, and the 'Date of earliest event reported' is also June 9, 2025.
What is the Commission File Number for Ligand Pharmaceuticals Inc.?
The Commission File Number is 001-33093.
Where is Ligand Pharmaceuticals Inc. headquartered?
Ligand Pharmaceuticals Inc.'s principal executive offices are located at 555 Heritage Drive, Suite 200, Jupiter, Florida 33458.
Does this filing indicate the outcome of the shareholder vote?
No, this filing only indicates that a submission of matters to a vote of security holders is being reported; it does not disclose the outcome.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding LIGAND PHARMACEUTICALS INC (LGNZZ).